Advanced age does not limit the benefits of sodium-glucose cotransporter 2 inhibitors in chronic kidney disease

1 hour ago 1
New probe uncovers the imaginable benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years oregon older with chronic kidney illness (CKD). The findings volition beryllium presented astatine ASN Kidney Week 2026, Oct. 22–25.
Read Entire Article